Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Milton, DT [1 ]
Kris, MG [1 ]
Azzoli, CG [1 ]
Gomez, JE [1 ]
Heelan, R [1 ]
Krug, LM [1 ]
Pao, W [1 ]
Pizzo, B [1 ]
Rizvi, NA [1 ]
Miller, VA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：646S / 646S
页数：1
相关论文
共 50 条
  • [21] A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)
    Papadimitrakopoulou, Vassiliki
    Soria, Jean-Charles
    Douillard, Jean-Yves
    Giaccone, Giuseppe
    Wolf, Juergen
    Crino, Lucio
    Cappuzzo, Frederico
    Sharma, Sunil
    Gross, Stefan H.
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S359 - S360
  • [22] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Nishiwaki, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [23] Phase ii trial with Docetaxel in patients (PTS) with non small cell lung cancer (NSCLC)
    Latreille, J
    Laberge, F
    Viallet, J
    Maksymiuk, A
    Shepherd, F
    Gelman, K
    Delorme, F
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1070 - 1070
  • [24] Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC).
    Khawaja, M. R.
    Younger, A.
    Funke, J. M.
    Waddell, M. J.
    Jones, D. R.
    Pollok, K.
    Prasad, N. K.
    Berry, W.
    Sandusky, G.
    Chiorean, E. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
    Su Jin Lee
    Jongtae Lee
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Young Suk Park
    Ho Yeong Lim
    Kyoung-Mee Kim
    In-Gu Do
    Sin-Ho Jung
    Dong-Seok Yim
    Won Ki Kang
    Investigational New Drugs, 2013, 31 : 1580 - 1586
  • [26] Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
    Lee, Su Jin
    Lee, Jongtae
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kim, Kyoung-Mee
    Do, In-Gu
    Jung, Sin-Ho
    Yim, Dong-Seok
    Kang, Won Ki
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1580 - 1586
  • [27] A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
    Sequist, L. V.
    Harb, W. A.
    Modiano, M.
    Jackman, D. M.
    Wong, K.
    Engelman, J. A.
    Nering, R.
    Onsum, M.
    Moyo, V. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC).
    Amato, R. J.
    Misellati, A.
    Khan, M.
    Chiang, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [30] A phase II trial of RAD001 in patients (PTS) with metastatic renal cell carcinoma (MRCC)
    Amato, R.
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    CANCER INVESTIGATION, 2007, 25 : 20 - 21
12345